[{"ID":"6810_15-2021_NCT02205125","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient is not eligible for the clinical trial because the trial is focused on colon cancer and the patient has pancreatic cancer.\n\n#2: The patient is eligible for the clinical trial because the trial is focused on polypectomy and the patient is scheduled to undergo polypectomy.\n\n#3: The patient is not eligible for the clinical trial because the trial is focused on colonoscopy and the patient has not undergone colonoscopy.\n\n#4: The patient is eligible for the clinical trial because the trial is focused on submucosal tissue and the patient has a mass in the left upper abdomen.","PROBA":0.9934734611},{"ID":"30737_65-2021_NCT02287506","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible","PROBA":0.9618235528},{"ID":"5294_12-2021_NCT01305148","TOPIC_YEAR":2021,"RESPONSE":"#1: No, the patient is not eligible for the clinical trial because the patient has Marfan's syndrome and known severe mitral valve prolapse with regurgitation, which is not related to warfarin or genetic testing.\n\n#2: Yes, the patient is eligible for the clinical trial because the patient is receiving genetic testing at therapy initiation, and the patient has a known genetic disorder (Marfan's syndrome) that may be relevant to the study.\n\nPlease select one of the above options as your answer.","PROBA":0.9908308129},{"ID":"6767_15-2021_NCT01903148","TOPIC_YEAR":2021,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial because she has chronic kidney disease (CKD) and anemia, which are both included in the study's inclusion criteria. Additionally, she is not currently receiving erythropoiesis stimulating agents (ESA), which is an exclusion criterion for the study.\n\n#2: No, the patient is not eligible for the clinical trial because she does not have CKD or anemia.\n\n#3: Yes, the patient is eligible for the clinical trial because she has CKD and anemia, which are both included in the study's inclusion criteria. However, she is currently receiving ESA, which is an exclusion criterion for the study.\n\n#4: No, the patient is not eligible for the clinical trial because she does not have CKD or anemia.\n\n#5: Yes, the patient is eligible for the clinical trial because she has CKD and anemia, which are both included in the study's inclusion criteria. Additionally, she is not currently receiving ESA, which is an exclusion criterion for the study.","PROBA":0.9922244988},{"ID":"35514_75-2021_NCT02098642","TOPIC_YEAR":2021,"RESPONSE":"#1: Hallux Mobilization in Patients With Parkinson's Disease\n\nThe patient is eligible for the clinical trial.\n\n\nThe patient is a 55-year-old man with Parkinson's disease, which is the primary inclusion criterion for the clinical trial. The patient also meets the exclusion criteria, as he does not have any other concomitant neurological conditions or joint disorders. Therefore, the patient is eligible for the clinical trial.","PROBA":0.9798842768},{"ID":"5456_12-2021_NCT03453853","TOPIC_YEAR":2021,"RESPONSE":"# Please answer with A, B, C, or D\n\nD","PROBA":0.956881432},{"ID":"30755_65-2021_NCT02411578","TOPIC_YEAR":2021,"RESPONSE":"#1: Based on the patient's history of type 1 diabetes and current symptoms of shortness of breath and fatigue during activities, the patient is likely eligible for the clinical trial.\n\n#2: The patient's use of 70\/30 Insulin and vitamin D supplements is relevant to the clinical trial, as it is a treatment for type 1 diabetes.\n\n#3: The patient's history of diabetic ketoacidosis in the past 12 months would be an exclusion criterion for the clinical trial, as it is a more severe form of hypoglycemia.\n\n#4: The patient's current age of 25 years is within the inclusion criteria age range of 18-65 years.\n\n#5: The patient's gender is male, which is an inclusion criterion for the clinical trial.\n\nTherefore, based on the information provided, the patient is likely eligible for the clinical trial.","PROBA":0.9871690714},{"ID":"35435_75-2021_NCT01399905","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible","PROBA":0.8994398024},{"ID":"11642_17-2022_NCT01874132","TOPIC_YEAR":2022,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n\n#2: No, the patient is not eligible for the clinical trial.\n\n#3: The patient is not eligible for the clinical trial due to the exclusion criteria.\n\n#4: The patient is eligible for the clinical trial, but the principal investigator should be consulted before enrolling the patient.","PROBA":0.9942943793},{"ID":"17065_36-2021_NCT01737138","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible\n\nThe patient is not eligible for the clinical trial because the trial is focused on patients with chronic kidney disease and resistant hypertension, and the patient does not have these conditions. The patient is obese and has sleep apnea, PCO, and dissatisfaction with her body shape, but these conditions are not related to the trial's focus.","PROBA":0.9991606433},{"ID":"6652_15-2021_NCT00921856","TOPIC_YEAR":2021,"RESPONSE":"#1: A: eligible\n\nThe patient is eligible for the clinical trial because she has a history of CAD and is currently being treated for it. The patient meets the inclusion criteria of being over 35 years old and having suspected CAD, and does not meet the exclusion criteria of being under 35 years old or having severe chronic obstructive pulmonary disease.","PROBA":0.9750583279},{"ID":"30417_65-2021_NCT00211510","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%","PROBA":0.9985199087},{"ID":"5322_12-2021_NCT01740583","TOPIC_YEAR":2021,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial because she has functional mitral valve regurgitation, which is the condition being studied in the trial. Additionally, she does not have any of the exclusion criteria listed in the trial, such as pregnancy, aortic stenosis, or previous mitral valve repair.\n\n#2: No, the patient is not eligible for the clinical trial because she has Marfan's syndrome, which is not listed as an inclusion criterion in the trial. Additionally, she has a known severe mitral valve prolapse, which may be considered a contraindication for the trial.\n\n#3: Yes, the patient is eligible for the clinical trial because she has functional mitral valve regurgitation, which is the condition being studied in the trial. Additionally, she does not have any of the exclusion criteria listed in the trial, such as pregnancy or previous mitral valve repair. However, her Marfan's syndrome may be a factor in her treatment and follow-up.","PROBA":0.9958977128},{"ID":"30870_65-2021_NCT03605979","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20ACE%20inhibitors%20and%20Beta%20blockers%20are%20excluded%20from%20the%20study%2C%20as%20they%20are%20not%20part%20of%20the%20study%E2%80%99s%20therapy%2C%20but%20the%20patient%E2%80%99s%20diabetes%20medications%20are%20eligible.%20The%20patient%E2%80%99s%20age%20(25)%20and%20diagnosis%20of%20type%201%20diabetes%20are%20both%20eligible%20for%20the%20study.%20The%20patient%E2%80%99s%20hearing%20loss%20and%20low%20vision%20are%20not%20excluded%20from%20the%20study%2C%20as%20they%20do%20not%20interfere%20with%20the%20study%E2%80%99s%20therapy.%20Therefore%2C%20the%20patient%20is%20eligible%20for%20the%20study.\n\nBased on the provided information and the criteria for the clinical trial, the patient would likely be considered eligible for the clinical trial since he meets the inclusion criteria and does not meet the specified exclusion criteria.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9898509754},{"ID":"6731_15-2021_NCT01611532","TOPIC_YEAR":2021,"RESPONSE":"#1: Based on the patient's history, the patient is eligible for the clinical trial.\n\n#2: The patient's age (70) is within the inclusion criteria range (18-65).\n\n#3: The patient's gender (female) is within the inclusion criteria range (all genders).\n\n#4: The patient's medical history (CAD, mitral valve prolapse, atrial fibrillation, hyperlipemia, hypertension, chronic kidney disease, hypothyroidism, anemia) is relevant to the clinical trial.\n\n#5: The patient's current condition (acute pancreatitis) is within the inclusion criteria range (acute pancreatitis).\n\n#6: The patient's recent history of diverticulitis is not an exclusion criterion.\n\n#7: The patient's recent history of coronary artery disease and angioplasty is not an exclusion criterion.\n\nTherefore, based on the information provided, the patient is eligible for the clinical trial.","PROBA":0.9795051677},{"ID":"6832_15-2021_NCT02426944","TOPIC_YEAR":2021,"RESPONSE":"#1: A: eligible\n\nThe patient is eligible for the clinical trial because she has atrial fibrillation and is at high risk of a cardioembolic event, which are both inclusion criteria for the trial. Additionally, she does not have any of the exclusion criteria listed, such as a thrombus in the LA or LAA, mechanical valve prosthesis, or previous LAA ligation during cardiac surgery.","PROBA":0.9843144637},{"ID":"6724_15-2021_NCT01534754","TOPIC_YEAR":2021,"RESPONSE":"#1: Based on the patient's history of CAD and recent abdominal mass with fever and vomiting, the patient is likely to be excluded from the clinical trial since the patient has acute diverticulitis, which is a complication of diverticular disease that is not included in the inclusion criteria.\n\n#2: The patient's history of hyperlipidemia, hypertension, and chronic kidney disease may be relevant to the patient's overall health and potential treatment, but these conditions are not directly related to diverticular disease or the clinical trial.\n\n#3: The patient's history of hypothyroidism and anemia may also be relevant to the patient's overall health and potential treatment, but these conditions are not directly related to diverticular disease or the clinical trial.\n\n#4: The patient's history of atrial fibrillation and mitral valve prolapse may be relevant to the patient's overall health and potential treatment, but these conditions are not directly related to diverticular disease or the clinical trial.\n\n#5: The patient's history of coronary artery disease and recent angioplasty is not directly related to diverticular disease or the clinical trial.\n\nTherefore, based on the patient's history and the inclusion and exclusion criteria of the clinical trial, the patient is likely to be excluded from the clinical trial.","PROBA":0.9918715611},{"ID":"6816_15-2021_NCT02243007","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible","PROBA":0.8959053531},{"ID":"5517_12-2021_NCT04156295","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20Patient%20Note:%20\n\nA 34-year-old woman with Marfan's syndrome and known severe mitral valve prolapse with regurgitation, who was planned for a MV repair but was lost to follow-up. She remains symptomatic and is now prepared to undergo mitral valve repair\/replacement surgery. EF of 65% on TTE. Past Medical History: Marfans Syndrome MVP with severe mitral regurgitation Gastric reflux disease History of gestational diabetes mellitus Hypertension with pregnancy Obesity c-section x 2 laser eye surgery cataract surgery foot surgery (shorten bone length)\n\nBased on the patient's note and the inclusion criteria of the clinical trial, the patient is eligible for the clinical trial because she has Marfan's syndrome and known severe mitral valve prolapse with regurgitation, which meets the inclusion criteria of the clinical trial. Additionally, the patient is prepared to undergo mitral valve repair\/replacement surgery, which is the same intervention being studied in the clinical trial. Therefore, the patient is eligible for the clinical trial.\n\nSo, the answer is A: eligible.","PROBA":0.9874766131},{"ID":"7077_15-2021_NCT04600063","TOPIC_YEAR":2021,"RESPONSE":"#1: Based on the patient's history of Coronary Artery Disease, Mitral Valve Prolapse, Atrial Fibrillation, Hyperlipemia, Hypertension, Chronic Kidney Disease, Hypothyroidism, Anemia, and the recent diagnosis of Pancreatic Adenocarcinoma, the patient would likely be considered eligible for the clinical trial.\n\n#2: The patient's history of Coronary Artery Disease, Mitral Valve Prolapse, Atrial Fibrillation, Hyperlipemia, Hypertension, Chronic Kidney Disease, Hypothyroidism, and Anemia may be relevant to the study, but the patient's recent diagnosis of Pancreatic Adenocarcinoma is the primary focus of the clinical trial.\n\n#3: The patient's history of Coronary Artery Disease, Mitral Valve Prolapse, Atrial Fibrillation, Hyperlipemia, Hypertension, Chronic Kidney Disease, Hypothyroidism, and Anemia may be relevant to the study, but the patient's recent diagnosis of Pancreatic Adenocarcinoma is the primary focus of the clinical trial.\n\n#4: The patient's history of Coronary Artery Disease, Mitral Valve Prolapse, Atrial Fibrillation, Hyperlipemia, Hypertension, Chronic Kidney Disease, Hypothyroidism, and Anemia may be relevant to the study, but the patient's recent diagnosis of Pancreatic Adenocarcinoma is the primary focus of the clinical trial.\n\n#5: The patient's history of Coronary Artery Disease, Mitral Valve Prolapse, Atrial Fibrillation, Hyperlipemia, Hypertension, Chronic Kidney Disease, Hypothyroidism, and Anemia may be relevant to the study, but the patient's recent diagnosis of Pancreatic Adenocarcinoma is the primary focus of the clinical trial.\n\n#6: The patient's history of Coronary Artery Disease, Mitral Valve Prolapse, Atrial Fibrillation, Hyperlipemia, Hypertension, Chronic Kidney Disease, Hypothyroidism, and Anemia may be relevant to the study, but the patient's recent diagnosis of Pancreatic Adenocarcinoma is the primary focus of the clinical trial.\n\n#7: The patient's history of Coronary Artery Disease, Mitral Valve Prolapse, Atrial Fibrillation, Hyperlipemia, Hypertension, Chronic Kidney Disease, Hypothyroidism, and Anemia may be relevant to the study, but the patient's recent diagnosis of Pancreatic Adenocarcinoma is the primary focus of the clinical trial.\n\n#8: The patient's history of Coronary Artery Disease, Mitral Valve Prolapse, Atrial Fibrillation, Hyperlipemia, Hypertension, Chronic Kidney Disease, Hypothyroidism, and Anemia may be relevant to the study, but the patient's recent diagnosis of Pancreatic Adenocarcinoma is the primary focus of the clinical trial.\n\n#9: The patient's history of Coronary Artery Disease, Mitral Valve Prolapse, Atrial Fibrillation, Hyperlipemia, Hypertension, Chronic Kidney Disease, Hypothyroidism, and Anemia may be relevant to the study, but the patient's recent diagnosis of Pancreatic Adenocarcinoma is the primary focus of the clinical trial.\n\n#10: The patient's history of Coronary Artery Disease, Mitral Valve Prolapse, Atrial Fibrillation, Hyperlipemia, Hypertension, Chronic Kidney Disease, Hypothyroidism, and Anemia may be relevant to the study, but the patient's recent diagnosis of Pancreatic Adenocarcinoma is the primary focus of the clinical trial.\n\nBased on the patient's history of Coronary Artery Disease, Mitral Valve Prolapse, Atrial Fibrillation, Hyperlipemia, Hypertension, Chronic Kidney Disease, Hypothyroidism, and Anemia, the patient would likely be considered eligible for the clinical trial. However, the primary focus of the clinical trial is the patient's recent diagnosis of Pancreatic","PROBA":0.9962534842}]
